Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Verona Pharma Reports Bronchodilator Data with RPL554 in COPD Patients

Published: Tuesday, January 15, 2013
Last Updated: Tuesday, January 15, 2013
Bookmark and Share
Data was presented at the 2012 European Respiratory Society Annual Congress in Vienna.

Verona Pharma plc has announced the completion and reporting of data from a clinical trial with its lead drug candidate, the dual PDE 3 and 4 inhibitor RPL554, in patients with chronic obstructive pulmonary disease (COPD).

The data was presented by the trial’s Principal Investigator, Professor Mario Cazzola, at the European Respiratory Society (ERS) Annual Congress in Vienna.

The Phase II trial was a placebo-controlled cross-over study in 12 patients with mild to moderate COPD and was carried out at the Tor Vergata Clinic at the University of Rome, Italy.

The data showed that a single dose of nebulized RPL554 to patients with COPD produced a rapid bronchodilator response, greater than a 15% increase in FEV1 (forced expiratory volume at 1 second).

This magnitude of bronchodilator response was significantly larger than that produced by placebo and appeared to be at least equivalent to that produced by a standard dose of the reference bronchodilator beta2-agonist salbutamol in these patients.

In addition, inhalation of 0.018 mg/kg of RPL554 was well tolerated and did not cause any significant adverse effects.

Professor Cazzola commented: “Our results with RPL554 show that this is a promising novel class of bronchodilator drug for the treatment of asthma and COPD.”

This completes the first bronchodilator study in mild to moderate COPD patients at the Tor Vergata Clinic in Rome and is an expansion of the pilot part of the study announced by the Company on 10 November 2011.

Dr. Jan-Anders Karlsson, CEO of Verona Pharma said: “These data with RPL554 in COPD patients confirms the bronchodilator activity that we have previously observed in a smaller group of COPD patients and in asthmatics. RPL554 has a very interesting profile with its rapid onset of action. In addition to its bronchodilator activity, we are evaluating its potential anti-inflammatory effect in the clinical trial that is currently on-going at the Medicines Evaluation Unit in Manchester.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

US Patent Granted for Verona Pharma’s RPL554
Company is currently carrying out clinical trials of the drug, RPL554.
Tuesday, January 01, 2013
Verona Pharma Appoints Manchester Clinical Research Facility to Carry Out Clinical Trial with RPL554
Enrollment of patients to start Q2, with results expected early Q4 2012.
Friday, March 09, 2012
Verona Pharma Successfully Completes £3.25 Million Placing
Placing to provide Company with sufficient working capital to finance RPL554 clinical trial programme.
Monday, December 12, 2011
Verona Pharma Announces Positive Results for RPL554 in Mild Asthma at Higher Doses
Verona has completed a successful trial in which 20 mild asthmatic subjects treated with either single doses of RPL554 or placebo administered via a nebulizer.
Wednesday, February 23, 2011
Verona Pharma Applies for Approval to Test RPL554 in UK Clinical Trials
RPL554 is Verona Pharma’s lead drug compound which is a long acting bronchodilator/anti-inflammatory drug belonging to a class of drugs known as a mixed PDE 3/4 inhibitor.
Monday, February 14, 2011
Scientific News
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!